NCT00095251View on ClinicalTrials.gov

MENDS Study: Trial in Ventilated ICU Patients Comparing an Alpha2 Agonist Versus a Gamma Aminobutyric Acid (GABA)-Agonist to Determine Delirium Rates, Efficacy of Sedation, Analgesia and Discharge Cognitive Status

PHASE2CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

August 31, 2007

Study Completion Date

December 31, 2016

Conditions

Delirium

Interventions

DRUG

Dexmedetomidine

a bolus dose of 1 μg/kg infused over 10 minutes followed by an infusion started at 0.15- 0.45 μg/kg/hr. Dexmedetomidine will be titrated every 10 minutes to achieve set target RASS score. The maximum dexmedetomidine infusion will be 1.5 μg/kg/hr.

DRUG

Lorazepam

Patients in the lorazepam arm will receive a bolus dose of 1-3 mg followed by an infusion started at 1-3 mg/hr. Lorazepam infusion will be titrated every 10 minutes to achieve set target RASS score. The maximum lorazepam infusion will be 10 mg /hr.

Trial Locations (1)

37232

Vanderbilt University Medical Center, Nashville

All Listed Sponsors

lead

Vanderbilt University

OTHER

NCT00095251 - MENDS Study: Trial in Ventilated ICU Patients Comparing an Alpha2 Agonist Versus a Gamma Aminobutyric Acid (GABA)-Agonist to Determine Delirium Rates, Efficacy of Sedation, Analgesia and Discharge Cognitive Status | Biotech Hunter | Biotech Hunter